Using ARVs as Prevention: Promise, Precautions and Potential for Drug Resistance
PrEP is a promising HIV prevention approach that involves use of antiretroviral (ARV) drugs that are normally used for treatment of HIV. But, should clinical trials find the strategy successful and PrEP is then rolled out as a prevention approach in at-risk communities, there is concern that virus resistant to the ARVs potentially would emerge and spread. What exactly is the risk and how can we avoid the consequences of "two trains on a collision course"? Two studies looked for answers. In one, a computer model that simulated the impact of PrEP on HIV prevention and drug resistance identified key factors that would influence the spread of HIV drug resistance. In a different take, laboratory studies suggest under what circumstances ARV-based gels could cause virus to become resistant. The same study tested different ARV gels to determine whether they can protect against strains of resistant virus known to be resistant against these ARVs or drugs in the same class.
Participants: Ume Abbas, M.D., Cleveland Clinic Foundation; Susan M. Schader, Ph.D., McGill University and McGill AIDS Centre, Montreal, Canada; John Mellors, M.D., University of Pittsburgh School of Medicine; Regina Osih, MD, MPH, University of the Witwatersrand, Johannesburg, South Africa. Moderator: Mitchell Warren, AVAC: Global Advocacy for HIV Prevention.
TUESDAY, May 25
Use of Lubricants, Unprotected Anal Sex and the Risk of HIV
The risk of acquiring HIV through unprotected anal sex is at least 20 times greater than with unprotected vaginal sex and increases if other infections are already present in the rectal lining. Could the use of lubricants at least certain kinds be another risk factor among men and women who engage in receptive anal intercourse? A study involving nearly 900 men and women in Baltimore and
|Contact: Lisa Rossi|
Microbicides 2010 (International Conference on Microbicides)